{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06307795",
            "orgStudyIdInfo": {
                "id": "ANS014004-I-US-01"
            },
            "organization": {
                "fullName": "Avistone Biotechnology Co., Ltd.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors",
            "officialTitle": "A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS014004 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-investigate-in-participants-with-locally-advanced-or-metastatic-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2024-04-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-05",
            "studyFirstSubmitQcDate": "2024-03-11",
            "studyFirstPostDateStruct": {
                "date": "2024-03-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Avistone Biotechnology Co., Ltd.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors."
        },
        "conditionsModule": {
            "conditions": [
                "Locally Advanced or Metastatic Solid Tumors"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 63,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ANS014004 Monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "Part 1 aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of ANS014004.\n\nPart 2 aims to determine the safety, tolerability and evaluate anti-tumor activity of ANS014004 as monotherapy in select solid tumors.",
                    "interventionNames": [
                        "Drug: ANS014004"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ANS014004",
                    "description": "Varying doses of ANS014004",
                    "armGroupLabels": [
                        "ANS014004 Monotherapy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Adverse Events (AEs)",
                    "description": "Number of patients with adverse events by system organ class and preferred term",
                    "timeFrame": "From the time of first dose to 28 days post last dose of ANS014004"
                },
                {
                    "measure": "Incidence of Serious Adverse Events (SAEs)",
                    "description": "Number of patients with serious adverse events by system organ class and preferred term",
                    "timeFrame": "From time of first dose to 28 days post last dose of ANS014004"
                },
                {
                    "measure": "Incidence of dose-limiting toxicities (DLT) as defined in the protocol",
                    "description": "Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol",
                    "timeFrame": "From time of first dose of ANS014004 to end of DLT period (approximately 30 days)"
                },
                {
                    "measure": "Incidence of baseline laboratory finding, ECG and vital signs changes",
                    "description": "measured by laboratory and vital sign variables over time including change from",
                    "timeFrame": "From time of first dose to 28 days post last dose of ANS014004"
                },
                {
                    "measure": "Proportion of patients with radiological response (ORR)",
                    "description": "Assessed by overall response rate (ORR) defined as the proportion of patients who have a confirmed complete or partial radiological response by the Investigator according to RECIST v1.1",
                    "timeFrame": "From date of first dose of ANS014004 until progression, or the last evaluable assessment in the absence of progression \uff08approximately 2 years)\uff09"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "The percentage or number of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST v1.1)",
                    "timeFrame": "From date of first dose of ANS014004 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)"
                },
                {
                    "measure": "Duration of Response (DoR)",
                    "description": "The percentage of patients with confirmed CR or PR or having SD maintained (RECIST v1.1)",
                    "timeFrame": "From date of first dose of ANS014004 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)"
                },
                {
                    "measure": "Disease Control Rate (DCR)",
                    "description": "From date of first dose of ANS014004 up until progression, or the last evaluable assessment in the absence of progression",
                    "timeFrame": "From date of first dose of ANS014004 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)"
                },
                {
                    "measure": "Progression free Survival (PFS)",
                    "description": "The time from first dose until RECIST 1.1 defined disease progression or death due to any cause",
                    "timeFrame": "rom date of first dose of ANS014004 up until date of progression or death due to any cause (approximately 2 years)"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "description": "The time from the date of the first dose of study treatment until death due to any cause",
                    "timeFrame": "From date of first dose of ANS014004 up until the date of death due to any cause (approximately 2 years)"
                },
                {
                    "measure": "Pharmacokinetics of ANS014004: Plasma PK concentrations",
                    "description": "Measurement of plasma concentrations of ANS014004, total antibody and total unconjugated warhead",
                    "timeFrame": "From date of first dose up until 28 days post last dose"
                },
                {
                    "measure": "Pharmacokinetics of ANS014004: Area under the concentration time curve (AUC)",
                    "description": "Measurement of PK parameters: Area under the concentration time curve (AUC)",
                    "timeFrame": "From date of first dose up until 28 days post last dose"
                },
                {
                    "measure": "Pharmacokinetics of ANS014004: Maximum plasma concentration of the study drug (C-max)",
                    "description": "Measurement of PK parameters: Maximum observed plasma concentration of the study drug (C-max)",
                    "timeFrame": "From date of first dose up until 28 days post last dose"
                },
                {
                    "measure": "Pharmacokinetics of ANS014004: Time to maximum plasma concentration of the study drug (T-max)",
                    "description": "Measurement of PK parameters: Time to maximum observed plasma concentration of the study drug (T-max)",
                    "timeFrame": "From date of first dose up until 28 days post last dose"
                },
                {
                    "measure": "Pharmacokinetics of ANS014004: Clearance",
                    "description": "Measurement of PK parameters: the volume of plasma from which the study drug is completely removed per unit time (Clearance)",
                    "timeFrame": "From date of first dose up until 28 days post last dose"
                },
                {
                    "measure": "Pharmacokinetics of ANS014004: Half-life",
                    "description": "Measurement of PK parameters: Terminal elimination half-life (t 1/2)",
                    "timeFrame": "From date of first dose up until 28 days post last dose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1\n* Life expectancy \u2265 12 weeks\n* Measurable disease per RECIST v1.1\n* Adequate organ and marrow function as defined in the protocol\n* With a pathogenetic MET alteration (including MET mutation, MET amplification, MET overexpression, MET fusion)\n\nExclusion Criteria:\n\n* Active infection including tuberculosis and HBV, HCV or HIV\n* Known active or untreated CNS metastases\n* Participants with carcinomatous meningitis or meningeal metastases, or spinal cord compression\n* Participants with serious cardiovascular or cerebrovascular diseases",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Avistone Clinical Study Information Center",
                    "role": "CONTACT",
                    "phone": "8610 84148921",
                    "email": "information.center@avistonebio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director Clinical Science",
                    "affiliation": "Beijing Avistone Biotechnology Co., Ltd.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Sarah Cannon Research Institute",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Advent Health",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32804",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "The University of Texas - MD Anderson Cancer Center",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "NEXT Oncology, Virginia",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Univ. of Washington Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109-1024",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        }
    },
    "hasResults": false
}